Literature DB >> 19219668

Low plasma levels of docosahexaenoic acid are associated with an increased relapse vulnerability in substance abusers.

Laure Buydens-Branchey1, Marc Branchey, Joseph R Hibbeln.   

Abstract

Low levels of some polyunsaturated fatty acids (PUFAs) could influence behaviors leading to the abuse of substances through their actions on serotonergic and dopaminergic mechanisms. Because substance abusers tend to have poor dietary habits, the possibility that a deficient intake of n-3 PUFAs, available from dietary sources only, and subsequent low n-3 plasma levels would predict their relapse rates was explored. Thirty-five patients admitted to substance abuse clinics were enrolled and followed for one year. Dietary questionnaires and blood samples were collected at baseline and on a quarterly basis, and relapse rates monitored on a monthly basis. Six patients dropped out shortly after study entry, 11 relapsed in the course of the study and dropped out, 7 relapsed but completed the study, and 11 did not relapse and completed the study. Non-relapsers were found to have significantly higher levels of docosahexaenoic acid (DHA) calculated as microg/ml and % TFA, when compared to relapsers (p = .031 and p = .010, respectively) and to relapsers and non-completers combined (p = .014 and p = .009, respectively). These pilot data suggest, but do not prove, the existence of a relationship between low levels of DHA and relapse vulnerability in some individuals who abuse substances. The study of the efficacy of n-3 supplements or of dietary modifications on relapse appears warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19219668     DOI: 10.1080/10550490802544003

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  7 in total

1.  Higher n-3 fatty acids are associated with more intense fenfluramine-induced ACTH and cortisol responses among cocaine-abusing men.

Authors:  Laure Buydens-Branchey; Marc Branchey; Joseph R Hibbeln
Journal:  Psychiatry Res       Date:  2011-06-11       Impact factor: 3.222

2.  Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison.

Authors:  Michael D Lewis; Joseph R Hibbeln; Jeremiah E Johnson; Yu Hong Lin; Duk Y Hyun; James D Loewke
Journal:  J Clin Psychiatry       Date:  2011-08-23       Impact factor: 4.384

3.  The effects of polyunsaturated fatty acids in alcohol dependence treatment--a double-blind, placebo-controlled pilot study.

Authors:  Marina N Fogaça; Ruth F Santos-Galduróz; Jaqueline K Eserian; José Carlos F Galduróz
Journal:  BMC Clin Pharmacol       Date:  2011-07-26

4.  Specific behavioral and cellular adaptations induced by chronic morphine are reduced by dietary omega-3 polyunsaturated fatty acids.

Authors:  Joshua Hakimian; Ani Minasyan; Lily Zhe-Ying; Mariana Loureiro; Austin Beltrand; Camille Johnston; Alexander Vorperian; Nicole Romaneschi; Waleed Atallah; Fernando Gomez-Pinilla; Wendy Walwyn
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

5.  Omega-3 for the Prevention of Alcohol Use Disorder Relapse: A Placebo-Controlled, Randomized Clinical Trial.

Authors:  Renata Pauluci; Ana Regina Noto; Daniela Fernandez Curado; Miguel Siqueira-Campos; Andréia Gomes Bezerra; José Carlos Fernandes Galduróz
Journal:  Front Psychiatry       Date:  2022-04-08       Impact factor: 4.157

6.  Long-Chain ω-3 Levels Are Associated With Increased Alcohol Sensitivity in a Population-Based Sample of Adolescents.

Authors:  Alexis C Edwards; Jon Heron; Joseph Hibbeln; Marc A Schuckit; Bradley T Webb; Matthew Hickman; Andrew G Davies; Jill C Bettinger
Journal:  Alcohol Clin Exp Res       Date:  2019-10-25       Impact factor: 3.455

7.  Brain docosahexaenoic acid [DHA] incorporation and blood flow are increased in chronic alcoholics: a positron emission tomography study corrected for cerebral atrophy.

Authors:  John C Umhau; Weiyin Zhou; Shantalaxmi Thada; James Demar; Nahed Hussein; Abesh K Bhattacharjee; Kaizong Ma; Sharon Majchrzak-Hong; Peter Herscovitch; Norman Salem; Abigail Urish; Joseph R Hibbeln; Stephen C Cunnane; Stanley I Rapoport; Jussi Hirvonen
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.